<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111118">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02129465</url>
  </required_header>
  <id_info>
    <org_study_id>CMV_transmission.CTIL</org_study_id>
    <nct_id>NCT02129465</nct_id>
  </id_info>
  <brief_title>Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy</brief_title>
  <acronym>CMV</acronym>
  <official_title>Correlates of Maternal Characteristics in CMV Infection in Pregnancy With Maternal-fetal Transmission.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Analysis of several characteristics of blood from pregnant women with CMV infection
      according to maternal-fetal transmission. These include CMV viral load, cytokine profile in
      response to in-vitro stimulation with CMV peptides, meticulous analysis of anti CMV
      antibodies, maternal DNA polymorphism and microarray of gene expression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal Cytomegalovirus infection in pregnancy may cause significant morbidity in the
      fetus. Intrauterine CMV transmission occurs mainly during primary maternal infections, with
      a maternal-fetal transmission rate of about 40%. The mechanisms dictating CMV intrauterine
      transmission are unknown, and transmission is currently thought to be dependent on multiple
      factors, including the maternal and fetal immune system.

      To investigate the mechanism of transmission approaching laboratory prediction of
      transmission, the investigators collect blood from pregnant women with primary CMV
      infection, and analyze several characteristics. These include CMV viral load, cytokine
      profile in response to in-vitro stimulation with CMV peptides, meticulous analysis of anti
      CMV antibodies, maternal DNA polymorphism and microarray of gene expression.

      These results will be analysed according to transmission as indicated by a positive culture
      / Polymerase chain transcription of amniotic fluid  or newborns urine / saliva.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Maternal-fetal transmission of CMV</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Positive CMV culture and / or PCR in amniotic fluid or newborns urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic congenital CMV</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Any clinical findings defining the patient as having symptomatic infection such as microcephaly, intra-cranial calcifications, sensory-neuronal hearing loss, etc.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pregnancy</condition>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Congenital Infection</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, plasma, peripheral blood mono-nuclear cells , DNA, RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant women with CMV infection who are referred to the 'CMV in Pregnancy clinic' in
        Shaare Zedek Medical Center.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women

          -  CMV infection: primary infection: (1) CMV-specific IgG seroconversion or (2)
             demonstration of low avidity CMV-specific IgG antibodies, (3) the primary appearance
             of CMV-specific IgM with no previous IgG, and (4) CMV DNA or viral products in blood
             Secondary infection:  appearance of CMV-specific IgM with positive IgG

        Exclusion Criteria:

          -  CMV status unclear

          -  spontaneous or induced abortion

          -  unknown fetal outcome
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yechiel Schlesinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yifat Eldar-Yedidia, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center, Jerusalem, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yechiel Schlesinger, MD</last_name>
    <phone>972-2-6555-197</phone>
    <email>s.yechiel@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yifat Eldar-Yedidia, Ph.D.</last_name>
    <phone>972-54-6878-093</phone>
    <email>yifat4@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yifat Eldar-Yedidia, Ph.D.</last_name>
      <phone>972-54-6878093</phone>
      <email>yifat4@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Yechiel Schlesinger</last_name>
      <phone>972-2-6555197</phone>
      <email>s.yechiel@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yechiel Schlesinger, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>May 1, 2014</lastchanged_date>
  <firstreceived_date>April 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Yechiel Schlesinger</investigator_full_name>
    <investigator_title>Head, division of pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>CMV</keyword>
  <keyword>pregnancy</keyword>
  <keyword>transmission</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
